1. Home
  2. IMNM vs CHRN Comparison

IMNM vs CHRN Comparison

Compare IMNM & CHRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Immunome Inc.

IMNM

Immunome Inc.

HOLD

Current Price

$17.97

Market Cap

2.5B

Sector

Health Care

ML Signal

HOLD

Logo ChronoScale Corporation Common Stock

CHRN

ChronoScale Corporation Common Stock

BUY

Current Price

$14.80

Market Cap

2.9B

Sector

Industrials

ML Signal

BUY

Company Overview

Basic Information
Metric
IMNM
CHRN
Founded
2006
2026
Country
United States
United States
Employees
N/A
N/A
Industry
Medicinal Chemicals and Botanical Products
Industrial Machinery/Components
Sector
Health Care
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
2.5B
2.9B
IPO Year
2020
2012

Fundamental Metrics

Financial Performance
Metric
IMNM
CHRN
Price
$17.97
$14.80
Analyst Decision
Strong Buy
Buy
Analyst Count
17
2
Target Price
★ $35.19
$28.50
AVG Volume (30 Days)
★ 1.4M
122.7K
Earning Date
11-05-2026
10-14-2026
Dividend Yield
N/A
N/A
EPS Growth
51.40
★ 92.67
EPS
N/A
★ N/A
Revenue
★ $6,941,000.00
N/A
Revenue This Year
N/A
$84.77
Revenue Next Year
$18,803.97
$603.10
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
★ N/A
52 Week Low
$14.64
$12.62
52 Week High
$30.06
$30.00

Technical Indicators

Market Signals
Indicator
IMNM
CHRN
Relative Strength Index (RSI) 35.71 36.17
Support Level $17.83 $12.62
Resistance Level $23.48 $22.29
Average True Range (ATR) 0.98 1.51
MACD 0.14 -0.19
Stochastic Oscillator 32.67 27.49

Price Performance

Historical Comparison
IMNM
CHRN

About IMNM Immunome Inc.

Immunome Inc is a biotechnology company focused on developing first-in-class targeted oncology therapies. The company specializes in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics. Its pipeline includes varegacestat, an investigational oral gamma secretase inhibitor that reported positive topline results in the Phase 3 RINGSIDE trial for progressing desmoid tumors; IM-1021, a ROR1 antibody-drug conjugate under evaluation in a Phase 1 trial; and IM-3050, a FAP-targeted radioligand therapy with IND clearance and a planned Phase 1 trial. The company is also advancing preclinical solid tumor ADCs, including IM-1617, IM-1340, and IM-1335.

About CHRN ChronoScale Corporation Common Stock

ChronoScale Holdings Corp is providing cloud services to customers at third-party colocation centers located in Colorado, Minnesota and Utah, such as artificial intelligence and machine learning developers, seeking to develop their products. It design, develop, and market exoskeleton and complementary products that augment human strength, endurance, and mobility. Its Cloud Business provides graphics processing unit (GPU) computing solutions that enable customers to execute critical workloads related to artificial intelligence (AI), machine learning (ML), rendering, and other High Performance Computing (HPC) tasks at scale in a capacity-constrained market. It has one operating segment Cloud Business.

Share on Social Networks: